...
首页> 外文期刊>The Journal of Nuclear Medicine >Conjoint Statement of the SNM, ACNM, and ABNM on Credentialing and Delineation of Privileges for Therapeutic Procedures Using Radiopharmaceuticals
【24h】

Conjoint Statement of the SNM, ACNM, and ABNM on Credentialing and Delineation of Privileges for Therapeutic Procedures Using Radiopharmaceuticals

机译:SNM,ACNM和ABNM关于使用放射性药物进行治疗程序的资格认定和划定的联合声明

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

'Teaching case files involving diagnostic and therapeutic nuclear medicine procedures should be available and should cover the full spectrum of clinical applications - There must be a mechanism for maintaining case records and treatment results to facilitate patient follow-up. . . ." d. Section IV.A.5.a.(l) "Residents must be able to provide patient care - Residents. . The minimum requirements for supervision and administration of therapeutic procedures using radiopharmaceuticals (defined in the ACGME Nuclear Medicine Program Requirements) include independently evaluating and treating, under supervision, a minimum of 10 cases of radioiodine therapy for hyperthyroidism, a minimum of 5 cases of radioiodine therapy for thyroid carcinoma, and a minimum of 3 cases of parenteral radionuclide therapy. Show less
机译:'涉及诊断和治疗性核医学程序的教学案例档案应该是可用的,并且应该涵盖整个临床应用范围-必须有一种维护案例记录和治疗结果的机制,以促进患者的随访。 。 。 ”。d。第IV.A.5.a.(l)节“居民必须能够提供患者护理-居民。 。使用放射性药物监督和管理治疗程序的最低要求(在ACGME核医学计划要求中定义)包括在监督下独立评估和治疗至少10例甲状腺功能亢进的放射性碘疗法,至少5例放射性碘疗法甲状腺癌,至少3例胃肠外​​放射性核素治疗。显示较少

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号